Bildkälla: Stockfoto

Bioinvent: BI-1607 on its Way to a Phase I/2a trial - Redeye

Redeye comments on Bioinvent’s submission of a CTA for BI-1607.

Redeye comments on Bioinvent’s submission of a CTA for BI-1607.
Börsvärldens nyhetsbrev
ANNONSER